A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 26
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : TOT
Long Form : time on treatment
No. Year Title Co-occurring Abbreviation
2023 Real-World Treatment and Outcomes of ALK-Positive Metastatic Non-Small Cell Lung Cancer in a Southeast Asian Country. ALK, NCTSD, NSCLC, OS
2022 Application of several machine learning algorithms for the prediction of afatinib treatment outcome in advanced-stage EGFR-mutated non-small-cell lung cancer. AUC, KM, ML, OS
2022 Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation. PMMTB, SOC
2022 Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective. AEs, AML, CR, CRi, DSA, EFS, HRU, ICERs, LY, OS, PSA, QALY, US
2022 First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea. CI, EGFR, NSCLCs, OS
2022 The Prognostic Impact of Radiotherapy Delays in Oropharynx Carcinoma and the Role of p16 Status. CI, CSS, HR, LRR, RT, TDs
2022 Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22. CI, CNS, EGFR, KCSG, NSCLC, ORR, OS
2021 Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study. mCRPC, NHAs, OS, US
2021 Dosing Schedules of Gemcitabine and nab-Paclitaxel for Older Adults With Metastatic Pancreatic Cancer. GA, OS
10  2021 Genomic and Molecular Profiling of Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma Treated with Immune Checkpoint Blockade Compared to Survival Outcomes. HNSCC, HPV, ICB, non-OP, OPSCC, R/M, rwOS
11  2021 Number needed to treat analysis applied to pembrolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer. COPE, NNT, NSCLC, OS, PD-L1, PFS, RMST
12  2021 Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors. CI, HR, ICIs, mUC, OS, OS
13  2021 Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non-small-cell lung cancer harboring EGFR mutations: Results from a real-world study in South Korea. CI, EGFR, NSCLC, OS, TKIs
14  2020 A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England. CE, DCF, LTTACC, MBG, MEAs, NMB, PSUB, SDM, VOI
15  2020 Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations. EGFR, NSCLC, QALMs
16  2020 Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia. GEM, nab-P, OS, PDAC, PFS
17  2020 The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. mUC, OS, PFS, QALYs
18  2019 Intensity Modulated Radiation Therapy Versus Volumetric Arc Radiation Therapy in the Treatment of Glioblastoma-Does Clinical Benefit Follow Dosimetric Advantage? GBM, IMRT, VMAT
19  2018 Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data. aRCC, HRU, RCC
20  2018 SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. DFS, OS, SCOT
21  2015 Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US. CI, HR, MBC, OS, PFS
22  2015 Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US. MBC, NSAI, PFS, TTC
23  2015 Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study. CI, HR, MBC, OS, PFS
24  2015 Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA. CT, ET, EVE, HR, MBC, PFS
25  2015 Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US. CI, HR, MBC
26  2012 Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution. mCRPC, OS, PSA, TFI